To expand the scope of service we provide, AiDD has established a strategic partnership with the Cascadia Drug Development Group, LLC that shares our values and our standards of quality, complementing our core competencies.
The Cascadia Drug Development Group (CDDG; www.thecddg.com) is a Pacific Northwest-based consulting and drug development group that offers a wide range of expertise within an integrated framework. CDDG was founded by seasoned industry experts who are passionate about drug discovery and whose mission is to elaborate a new virtual model for therapeutic development.
CDDG can provide strategic oversight of drug development, from discovery to early clinical development. The founders have a strong scientific background in immunology and support a number of therapeutic areas, including inflammatory and autoimmune disease, infectious disease, metabolic disease and oncology. Through their network of vetted affiliates, they offer subject matter expertise in such areas as toxicology, PKDM, biomarkers, regulatory and patent law and early clinical operations. CDDG utilizes a flexible and virtual structure, which allows them to adapt to client needs and reduce overall costs. Their operating model is well-suited to highly interactive and efficient de-risking of projects and maximizing the value of client programs.
Ben Perry, PhD
Ben is a co-founder of AiDD and has broad medicinal chemistry experience covering multiple therapeutic areas (e.g. inflammation, pain, neurodegeneration & psychiatry) and gene families (e.g. kinases, integrins & GPCRs). As Associate Research Director at Addex Therapeutics (2008-2013), Ben led multiple drug discovery projects at various stages of development from hit identification to IND filing. He also co-led the identification and assessment of new technologies. At UCB Pharma, from 2005-2008, Ben was Principal Scientist, responsible for project management in medicinal chemistry, chemoinformatic initiatives and technology evaluation. At Celltech, as Senior Scientist, he was responsible for chemical library analysis and improvement. Ben is sole author on a patent for VLA-4 inhibitor (sold by UCB to Biogen) and co-authored 12 peer-reviewed publications and 18 patents. He holds a PhD in organic chemistry from Imperial College London.